RenovoDerm is one of several biotech startups housed at Ohio State University and backed by Columbus-based Ikove Venture Partners.
Columbus-based RenovoDerm has hired its first vice president of sales and marketing.
Michael Morello joins the company following recent Food and Drug Administration clearance for Phoenix Wound MatrixTM, a non-woven, fibrous graft used by medical staff for wound treatment.
“Michael has a proven history of commercializing high-performing sales teams, and he has a leadership style that fosters a culture of high-engagement and execution excellence,” says Ross Kayuha, CEO of RenovoDerm, in a release.
Morello has more than 20 years of industry experience, including 12 years in leadership roles with Amylin Pharmaceuticals, Shire Regenerative Medicine and Osiris Therapeutics. Most recently, he founded a medical distribution company that delivered wound care products and technologies to the federal government and private commercial accounts.
RenovoDerm is a subsidiary of ParaGen Technologies, which is based at the SciTech campus at Ohio State University, and Columbus-based Ikove Venture Partners.